Home / Conditions / Type 1 Diabetes / International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #5: Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance Part 5 of 6

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #5: Classification of Diabetes Mellitus and Other Categories of Glucose Intolerance Part 5 of 6

Jan 5, 2016

DeFronzoCoverDiabetes in children and youth

Type 1 diabetes in children and youth is typically characterized by weight loss, polyuria, polydipsia, blurring of vision, very high plasma glucose concentrations, and ketonuria. The diagnosis is usually very clear with high random glucose values, and there is rarely a need to investigate with an oral glucose tolerance text (OGTT). Type 2 diabetes in children is associated with milder symptoms and is often associated with obesity. In these cases, diagnosis is made using any one of OGTT, fasting plasma glucose, or HbA1c, with preference for HbA1c as there is no requirement to fast. However, there is still debate as to the use of the latter in children [65].

Classification of diabetes in youth poses special problems. Although type 1 diabetes remains the most common form of diabetes in youth of European background, type 2 diabetes is increasingly common, especially among adults at particularly high risk of type 2 diabetes. With the increase in obesity over the last 20 years, there has been an increase in type 2 diabetes in children especially among ethnicities at high risk as well as an increase in the number of children with type 1 who are overweight. Type 2 diabetes may also be present in youth with ketosis or ketoacidosis, which serves only to compound the problem further. While a practical delineation between these may be the use of insulin, it can no longer be assumed that those on insulin are type 1. Other investigations which could provide insight include measurement of C-peptide, characteristic type 1 antibodies, for example anti-GAD antibodies, and the monitoring of endogenous insulin secretion over time [17].

There has also been an increase in the number of children and adolescents with a mixture of the two types of diabetes, that is, subjects who are obese and/or with signs of insulin resistance as well as being positive for markers of autoimmunity to β cells. These cases present a problem under the current classification as they present with an overlapping phenotype of both type 1 and type 2 diabetes and have been referred to as hybrid diabetes, double diabetes, or latent autoimmune diabetes in youth (LADY) [66]. In such children, presentation of double diabetes is similar to LADA in adults.However, unlike LADA, little is known about the prevalence of double diabetes or the prevalence and significance of autoimmune markers in children. In addition, whether autoimmune-positive youth with double diabetes progress more rapidly to insulin dependence than those with type 2 diabetes without is not known. This is particularly important as these children/youth could be at risk for complications associated with β-cell dysfunction, as well as macro- and microvascular complications of type 2 diabetes. It has been suggested that the current classification of diabetes should be revised to include this new phenotype [66].

Another challenge among young people is the possibility of misdiagnosis of monogenic diabetes as type 1 and type 2. As noted previously, monogenic diabetes results from the inheritance of mutation(s) in a single gene that regulates β-cell function or less commonly in genes related to insulin resistance.

The clinical characteristics of a child with monogenic diabetes compared to children and youth with type 1 and type 2 are shown in Table 1.5. Monogenic diabetes should be considered in a child initially diagnosed as type 1 who has been diagnosed at less than 6 months of age, has a family history of diabetes with a parent affected, evidence of endogenous insulin production outside the “honeymoon” phase of diabetes with detectable C-peptide, and the absence of pancreatic islet autoantibodies (measured at diagnosis) [67].


In children with an initial diagnoses of type 2, a diagnosis of monogenic diabetes should be considered in the following circumstances: when the child is not obese or other diabetic family members have weight in the normal range, and the child does not have acanthosis nigricans; when the child is from an ethnic group with a low prevalence of type 2 diabetes and when there is no evidence of insulin resistance with normal fasting C-peptide levels [24,68].

In scenarios when monogenic diabetes is misdiagnosed as type 1 or 2, the aforementioned criteria should be considered as a whole rather than individually and are not absolute. DNA testing is now also available for diagnosis of monogenic diabetes.


Diabetes is characterized by hyperglycemia, and thus diagnostic tests focus on establishing elevated blood glucose levels [69]. A casual blood glucose, fasting glucose or an OGTT of 75 grams may be performed. For children, the oral glucose load is proportional to body weight at 1.75 g per kg body weight. Recently, HbA1c has been added as an acceptable and reliable means of diagnosing diabetes (discussed later). The cutpoints for the diagnosis of diabetes are listed in Table 1.6.


In the absence of symptoms clearly attributable to diabetes, a diagnosis should not be based on a single measurement, but requires results within the diabetes range on two separate days.

The most notable change in diagnostic criteria in recent years is the recommendation by the ADA and WHO to use HbA1c for diagnosis of diabetes. A summary of the evolution of this decision is described in the following section.

Diagnosis of diabetes using HbA1c

HbA1c is a hemoglobin variant primarily composed of glycohemoglobin, which is formed by the nonenzymatic attachment of glucose to hemoglobin [70]. It was first identified in 1968 by Rabar, who noted it was associated with diabetes. By 1980, its clinical utility as a marker of glycemic control had been recognized. By the 1990s, supported by strong evidence from two studies, the Diabetes Control and Complications Trial [71] and the United Kingdom Prospective Diabetes Study [72], and the development of new high through put methods and improved coefficients of variation (CV), HbA1c had become the cornerstone marker in the monitoring of diabetes. In more recent years, a US national glycohemoglobin standardization program has been established and the International Federation of Clinical Chemistry (IFCC) has taken the lead to ensure that HbA1c assays are standardized. In 2011, the units of reporting were also changed from percentage points to IFCC mmol/mol. After a period of dual reporting, HbA1c will be reported in mmol/mol in many countries.

With some improvement in the assay and standardization of HbA1c, together with evidence from key trials demonstrating the importance of intensive glycemic control (as reflected by HbA1c levels) in reducing the risk of microvascular complications of diabetes, the move from using glucose for diagnosis to HbA1c had begun to gather support. However, concerns over standardization of the HbA1c assays and over other factors that may affect HbA1c continued to dampen the enthusiasm for use of HbA1c for diagnosis. In the last 10 years, however, several

developments have resulted in the incorporation of HbA1c into the diagnostic armamentarium.There has been significant improvement in the assays of HbA1c [73], analysis from eight different studies showed that HbA1c is as strongly related to the presence of diabetic retinopathy as are blood glucose levels [74], and HbA1c is strongly predictive of macrovascular outcomes and mortality [75,76].

The advantages of using HbA1c for diagnosis are clear. Firstly, HbA1c has far less day-to-day biological variation than fasting or 2-hour glucose [77]. Secondly, HbA1c is stable for one week at room temperature after collection while glucose is susceptible to glycolysis despite the use of fluoride oxalate to preserve the sample. Thirdly, unlike glucose measurement, there is no requirement for the patient to fast. Finally, glucose levels are also susceptible to modification by short-term lifestyle intervention while HbA1c reflects glycemia over a period of 3 to 4 months.

The major disadvantage of HbA1c is that there are a number of nonglycemic conditions that interfere with the assay. In particular, alterations of red blood cell turnover (e.g. kidney failure,

hematinic deficiencies, hemolysis, acute blood loss, pregnancy, and erythropoietin therapy) may affect the relationship between HbA1c and recent glycemia. The other important disadvantage is the need for a laboratory to use an IFCC aligned assay and be part of a standardization program, which may not be possible in developing countries.

Cutpoints of HbA1c have been set using similar methods to those adopted for the setting of blood glucose criteria. Cross-sectional data from 47,364 individuals from 12 countries reported that the threshold for diabetes-specific retinopathy was 6.3% (45 mmol/mol−1), with an optimal decision limit of 6.5% [74]. This latter cutpoint has been adopted by the ADA and WHO as an appropriate cutpoint for diabetes.

Although support for the use of HbA1c for diagnosis of diabetes has increased over the years, several questions about its suitability remain. For example, what should be the appropriate HbA1c ranges for pre-diabetes or intermediate glycemia? The ADA suggested that 5.7–6.5% (39–48 mmol/mol−1) should be used [5] to indicate intermediate glycemia while the WHO [78] suggested that levels of HbA1c below 6.5% may indicate intermediate glycemia but were reluctant to indicate a precise lower cutpoint. An international expert committee suggested that those with HbA1c between 6.0–6.5% (42–48 mmol mol−1) could be considered at high risk, and should be targeted for diabetes prevention activities [79].

A further concern about moving from glucose to HbA1c to diagnose diabetes is that we will observe a change in prevalence of diabetes, as an elevated HbA1c does not identify exactly the same individuals as does an elevated blood glucose. It should, however, be noted that a similar discrepancy in individuals identified also applies to diagnosis by fasting glucose compared to diagnosis by 2-hour plasma glucose in the OGTT.

In general, the use of HbA1c for diagnosis of diabetes results in a lower prevalence of diabetes with the magnitude of the difference between blood glucose-based prevalence and HbA1c-based prevalence varying widely between populations [80].

Diagnosis of diabetes using HbA1c is now recommended by both the ADA and WHO as detailed in Table 1.6. As discussed earlier, it is important to ensure that the HbA1c assay used meets stringent quality assurance test and is aligned with the IFCC standardization program. It is also important to ensure that there are no clinical conditions that preclude its accurate measurement.


  1. World Health Organization (WHO): Diabetes Mellitus. Report of a WHO Expert Committee. Technical Report Series 310. Geneva: WHO, 1965.
  2. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–1057.
  3. World Health Organization: WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva: WHO, 1980.
  4. World Health Organization: Diabetes mellitus. Report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985, p. 727.
  5. American Diabetes Association (ADA): Diagnosis and classification of diabetes mellitius. Diabetes Care 2011;34(S1):S62–69.
  6. Kuzuya T, Matsuda A: Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997;20:219–220.
  7. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus.Geneva:WHO, 1999. Report No.WHO/NCD/NCS/99.2.
  8. Tuomi T, Groop L, Zimmet P, et al.: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin dependent onset of disease. Diabetes 1993;42:359–362.
  9. Atkinson M, Maclaren N: The pathogenesis of insulin-dependent diabetes mellitus. New England Journal of Medicine 1994;331:1428–1436.
  10. McLarty D, Atharde I, Bottazzo G, et al.: Islet cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans. Diabetes Research and Clinical Practice 1990;9:219–224.
  11. Ahrén B, Corrigan C: Intermittant need for insulin in a subgroup of diabetic patients in Tanzania. Diabetic Medicine 1984;2:262–264.
  12. Billings LK, Florez JC: The genetics of type 2 diabetes: what have we learned from GWAS? Annals of the New York Academy of Sciences 2010;1212:59–77.
  13. Kissebah A, Vydelingum N, Murray R, et al.: Relation of body fat distribution to metabolic complications of obesity. Journal of Clinical Endocrinology & Metabolism 1982;54:254–260.
  14. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15:815–819.
  15. Gill GV, Mbanya JC, Ramaiya KL, Tesfaye S: A sub-Saharan African perspective of diabetes. Diabetologia 2009;52:8–16.
  16. Sobngwi E, Mauvais-Jarvis F, Vexiau P, et al.: Diabetes in Africans. Part 2: Ketosis-prone atypical diabetes mellitus. Diabetes & Metabolism 2002;28:5–12.
  17. Banerji M, Chaiken R, Huey H, et al.: GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of HLA DR3 and DR4. Flatbush diabetes. Diabetes 1994;13:741–745.
  18. Meigs JB, Shrader P, Sullivan LM, et al.: Genotype score in addition to common risk factors for prediction of type 2 diabetes. New England Journal of Medicine 2008;359:2208–2219.
  19. Hattersley A, Bruining J, Shield J, et al.: ISPAD Clinical Practice Consensus Guidelines 2006–2007. The diagnosis and management of monogenic diabetes in children. Pediatric Diabetes 2006;7:352–360.
  20. Vionnet N, Stoffel M, Takeda J, et al.: Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:721–722.
  21. Murphy R, Ellard S, Hattersley AT: Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nature Clinical Practice Endocrinology and Metabolism 2008;4:200–213.
  22. Spyer G, Macleod KM, Shepherd M, et al.: Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabetic Medicine 2009;26:14–18.
  23. Stride A, Vaxillaire M, Tuomi T, et al.: The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002;45:427–435.
  24. Hattersley A, Bruining J, Shield J, et al.: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl 12):33–42.
  25. Iafusco D, Stazi MA, Cotichini R, et al.: Permanent diabetes mellitus in the first year of life. Diabetologia 2002;45:798–804.
  26. Ellard S, Flanagan SE, Girard CA, et al.: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. American Journal of Human Genetics 2007;81:375–382.
  27. Rigoli L, Di Bella C: Wolfram syndrome 1 and Wolfram syndrome 2. Current Opinion in Pediatrics 2012;24:512–517.
  28. Maassen JA, Kadowaki T: Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetologia 1996;39:375–382.
  29. Robbins DC, Shoelson SE, Rubenstein AH, Tager HS: Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion. Journal of Clinical Investigation 1984;73:714–719.
  30. Haneda M, Polonsky KS, Bergenstal RM, et al.: Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. New England Journal of Medicine 1984;310:1288–1294.
  31. Johns DR: Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. New England Journal of Medicine 1995;333:638–644.
  32. Semple RK, Savage DB, Cochran EK, et al.: Genetic syndromes of severe insulin resistance. Endocrine Reviews 2011;32:498–514.
  33. Gullo L, Pezzilli R, Morselli-Labate AM: Diabetes and the risk of pancreatic cancer. New England Journal of Medicine 1994;331: 81–84.
  34. Permert J, Larsson J, Westermark GT, et al.: Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. New England Journal of Medicine 1994;330:313–318.
  35. Utzschneider KM, Kowdley KV: Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nature Reviews Endocrinology 2010;6:26–33.
  36. Yajnik CS, Shelgikar KM, Naik SS, et al.: The ketoacidosis-resistance in fibro-calculous-pancreatic-diabetes. Diabetes Research and Clinical Practice 1992;15:149–156.
  37. Krejs GJ,Orci L,Conlon JM, et al.: Somatostatinoma syndrome. Biochemical, morphologic and clinical features. New England Journal of Medicine 1979;301:285–292.
  38. Pandit MK, Burke J, Gustafson AB, et al.: Drug-induced disorders of glucose tolerance. Annals of Internal Medicine 1993;118: 529–540.
  39. Miller LV, Stokes JD, Silpipat C: Diabetes mellitus and autonomic dysfunction after vacor rodenticide ingestion. Diabetes Care 1978; 1:73–76.
  40. Assan R, Perronne C,Assan D, et al.: Pentamidine-induced derangements of glucose homeostasis. Diabetes Care 1995;18:47–55.
  41. Madziarska K: New-onset posttransplant diabetes mellitus begins in the dialysis period. Journal of Renal Nutrition 2012;22:162–165.
  42. Drachenberg CB, Klassen DK, Weir MR, et al.: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68:396–402.
  43. Penfornis A, Kury-Paulin S: Immunosuppressive drug-induced diabetes. Diabetes & Metabolism 2006;32:539–546.
  44. Fabris P, Betterle C, Floreani A, et al.: Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.
  45. Sattar N, Preiss D, Murray HM, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742.
  46. Preiss D, Seshasai SR, Welsh P, et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2564.
  47. Wang KL, Liu CJ, Chao TF, et al.: Statins, risk of diabetes, and implications on outcomes in the general population. Journal of the American College of Cardiology 2012;60(14):1231–1238.
  48. Guo JJ, Keck PE, Jr,, Corey-Lisle PK, et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry 2006;67:1055–1061.
  49. Kalra S, Kalra B, Agrawal N, Unnikrishnan A: Understanding diabetes in patients with HIV/AIDS. Diabetology and Metabolic Syndrome 2011;3:2.
  50. De Wit S, Sabin CA, Weber R, et al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224–1229.
  51. Fleischman A, Johnsen S, Systrom DM, et al.: Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. American Journal of Physiology—Endocrinology and Metabolism 2007;292: E1666–1673.
  52. Lansang MC, Hustak LK: Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleveland Clinical Journal of Medicine 2011;78:748–756.
  53. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. New England Journal of Medicine 2005;353:1711–1723.
  54. van Raalte DH, Nofrate V, Bunck MC, et al.:Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthymen. European Journal of Endocrinology 2010;162:729–735.
  55. Forrest JM, Menser MA, Burgess JA: High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2:332–334.
  56. King ML, Bidwell D, Shaikh A, et al.: Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus. Lancet 1983;1(8339):1397–1399.
  57. Karjalainen J, Knip M, Hyoty H, et al.: Relationship between serum insulin antibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of Type I (insulin-dependent) diabetes. Diabetologia 1988;31: 146–152.
  58. Pak C, Eun H-M, McArthur R, Yoon J: Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988;II:1–4.
  59. Hirata Y, Ishizu H, Ouchi N, et al.: Insulin autoimmunity in a case of spontaneous hypoglycaemia. Journal of the Japan Diabetes Society 1970;13:312–320.
  60. Solimena M, De Camilli P: Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends in Neuroscience 1991;14:452–457.
  61. Flier JS: Lilly Lecture: syndromes of insulin resistance: from patient to gene and back again. Diabetes 1992;41:1207–1219.
  62. Khan C, Baird K, Flier JS, Jarret D: Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action. Journal of Clinical Investigation 1977;60:1094–1106.
  63. Tsokos GC, Gorden P, Antonovych T, et al.: Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Annals of Internal Medicine 1985;102:176–181.
  64. Moran A, Brunzell C, Cohen RC, et al.: Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697–2708.
  65. Azzopardi P, Brown AD, Zimmet P, et al.: Type 2 diabetes in young Indigenous Australians in rural and remote areas: diagnosis, screening, management and prevention. Medical Journal of Australia 2012;197:32–36.
  66. Pozzilli P,Guglielmi C:Double diabetes: a mixture of type 1 and type 2 diabetes in youth. Endocrine Development 2009;14:151–166.
  67. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification. In:Hanas R,Donaghue KC, Klingensmith G, et al. (eds.) Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. Brussels: International Diabetes Federation, 2011.
  68. Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl 12):3–12.
  69. World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva: WHO, 2006.
  70. Peterson KP, Pavlovich JG, Goldstein D, et al.: What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. Clinical Chemistry 1988;44:1951–1958.
  71. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:977–986.
  72. UKPDS (UK Prospective Diabetes Study Group): Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
  73. Little RR, Rohlfing CL, Sacks DB: Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clinical Chemistry 2011;57:205–214.
  74. Colagiuri S, Lee CM, Wong TY, et al.: Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145–150.
  75. Khaw KT, Wareham N, Bingham S, et al.: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of Internal Medicine 2004;141:413–420.
  76. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
  77. Sacks DB: A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518–523.
  78. World Health Organization: Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitius. Abbreviated report of a WHO consultation. Geneva: WHO, 2011.
  79. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334.
  80. Christensen DL, Witte DR, Kaduka L, et al.: Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580–582.
  81. Metzger BE, Lowe LP, Dyer AR, et al.: Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine 2008;358: 1991–2002.
  82. Metzger BE, Gabbe SG, Persson B, et al.: International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676–682.
  83. Santaguida PL, Balion C, Hunt D, et al.: Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary) 2005; 1–11.
  84. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Medicine 2002;19:708–723.
  85. Shaw JE, Zimmet PZ, Hodge AM, et al.: Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34–39.
  86. Gabir MM, Hanson RL, Dabelea D, et al.: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113–1118.
  87. Ford ES, Zhao G, Li C: Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology 2010;55:1310–1317.
  88. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167.
  89. American Diabetes Association: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–1197.